These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27565972)

  • 1. Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice.
    Soen S; Umemura T; Ando T; Kamisaki T; Nishikawa M; Muraoka R; Ikeda Y; Takeda K; Osawa M; Nakamura T
    J Bone Miner Metab; 2017 Jul; 35(4):419-427. PubMed ID: 27565972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
    Hagino H; Kishimoto H; Ohishi H; Horii S; Nakamura T
    Bone; 2014 Feb; 59():44-52. PubMed ID: 24184313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis.
    Soen S; Kishimoto H; Hagino H; Sone T; Ohishi H; Fujimoto T; Sasaki E; Tanaka S; Sugimoto T
    J Bone Miner Metab; 2020 Jan; 38(1):86-98. PubMed ID: 31420748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan.
    Sugimoto T; Inoue D; Maehara M; Oikawa I; Shigematsu T; Nishizawa Y
    J Bone Miner Metab; 2019 Jul; 37(4):730-740. PubMed ID: 30523414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study.
    Ito M; Tobinai M; Yoshida S; Hashimoto J; Nakamura T
    J Bone Miner Metab; 2017 Jan; 35(1):58-64. PubMed ID: 26614597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fracture risk remains reduced one year after discontinuation of risedronate.
    Watts NB; Chines A; Olszynski WP; McKeever CD; McClung MR; Zhou X; Grauer A
    Osteoporos Int; 2008 Mar; 19(3):365-72. PubMed ID: 17938986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
    Nakamura T; Fukunaga M; Nakano T; Kishimoto H; Ito M; Hagino H; Sone T; Taguchi A; Tanaka S; Ohashi M; Ota Y; Shiraki M
    Osteoporos Int; 2017 Jan; 28(1):389-398. PubMed ID: 27631091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.
    Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
    J Bone Miner Metab; 2009; 27(2):168-74. PubMed ID: 19183836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
    Ringe JD; Farahmand P; Faber H; Dorst A
    Rheumatol Int; 2009 Jan; 29(3):311-5. PubMed ID: 18762944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis.
    Park SY; Kang MI; Park HM; Rhee Y; Moon SH; Yoon HK; Koh JM; Chang JS; Kim IJ; Won YY; Park YS; Choi H; Shin CS; Yoon TR; Yun SC; Chung HY;
    Arch Osteoporos; 2019 Dec; 15(1):3. PubMed ID: 31820121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
    Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
    Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen.
    Kishimoto H; Fukunaga M; Kushida K; Shiraki M; Itabashi A; Nawata H; Nakamura T; Ohta H; Takaoka K; Ohashi Y;
    J Bone Miner Metab; 2006; 24(5):405-13. PubMed ID: 16937274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
    Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data.
    Gu JM; Wang L; Lin H; Chen DC; Tang H; Jin XL; Xia WB; Hu YQ; Fu WZ; He JW; Zhang H; Wang C; Yue H; Hu WW; Liu YJ; Zhang ZL
    Acta Pharmacol Sin; 2015 Jul; 36(7):841-6. PubMed ID: 26051110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice.
    Baxter I; Rogers A; Eastell R; Peel N
    Osteoporos Int; 2013 Mar; 24(3):941-7. PubMed ID: 22872068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Kendler DL; Marin F; Zerbini CAF; Russo LA; Greenspan SL; Zikan V; Bagur A; Malouf-Sierra J; Lakatos P; Fahrleitner-Pammer A; Lespessailles E; Minisola S; Body JJ; Geusens P; Möricke R; López-Romero P
    Lancet; 2018 Jan; 391(10117):230-240. PubMed ID: 29129436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
    Kanaji A; Higashi M; Namisato M; Nishio M; Ando K; Yamada H
    Lepr Rev; 2006 Jun; 77(2):147-53. PubMed ID: 16895071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.